Mariko Harada-Shiba

Title: Mariko Harada-Shiba: Innovator in Antisense Nucleic Acid Technology

Introduction

Mariko Harada-Shiba is a prominent inventor based in Osaka, Japan. She has made significant contributions to the field of pharmaceutical products, particularly in the development of therapeutic agents for diseases associated with high LDL cholesterol levels. Her innovative work has led to the creation of a unique oligonucleotide conjugate that targets the human PCSK9 gene.

Latest Patents

Mariko Harada-Shiba holds a patent for an antisense nucleic acid targeting PCSK9. This patent describes an oligonucleotide conjugate that comprises an oligonucleotide and two or more linearly connected asialoglycoprotein receptor-binding molecules. The oligonucleotide includes a locked nucleoside analog with a bridging structure between the 4' and 2' positions. It is complementary to the human PCSK9 gene and exhibits inhibitory activity on its expression. This invention has potential applications in the pharmaceutical industry, particularly for developing therapeutic agents aimed at lowering LDL cholesterol levels.

Career Highlights

Mariko Harada-Shiba is affiliated with the National Cerebral and Cardiovascular Center, where she continues her research and development efforts. Her work has garnered attention for its innovative approach to addressing cardiovascular health issues.

Collaborations

Some of her notable coworkers include Fumito Wada and Satoshi Obika, who have collaborated with her on various research projects.

Conclusion

Mariko Harada-Shiba's contributions to antisense nucleic acid technology highlight her role as a leading inventor in the pharmaceutical field. Her innovative patent targeting PCSK9 represents a significant advancement in the development of treatments for high cholesterol levels.